Keywords
Last Name
Institution

Christopher E. Walsh

TitleASSOCIATE PROFESSOR
InstitutionMount Sinai
DepartmentHematology and Medical Oncology
Address5 East 98th Street
12th Floor
New York NY 10029
Phone212-241-8303
Fax212-722-6079

     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Lewis KB, Hughes RJ, Epstein MS, Josephson NC, Kempton CL, Kessler CM, Key NS, Howard TE, Kruse-Jarres R, Lusher JM, Walsh CE, Watts RG, Ettinger RA, Pratt KP. Phenotypes of allo- and autoimmune antibody responses to FVIII characterized by surface plasmon resonance. PLoS One. 2013; 8(5):e61120.
      View in: PubMed
    2. Walsh CE, Batt KM. Hemophilia clinical gene therapy: brief review. Transl Res. 2013 Apr; 161(4):307-12.
      View in: PubMed
    3. Ward P, Walsh CE. Targeted integration of a rAAV vector into the AAVS1 region. Virology. 2012 Nov 25; 433(2):356-66.
      View in: PubMed
    4. Valentino LA, Walsh CE, Reding MT, Young GA, Levendoglu-Tugal O, Cooper DL. Patient- and caregiver-reported bleeding symptoms and reasons for starting and stopping treatment with recombinant factor VIIa: analysis of the Dosing Observational Study in Haemophilia (DOSE). Haemophilia. 2012 Jul; 18(4):554-60.
      View in: PubMed
    5. Young G, Shapiro AD, Walsh CE, Gruppo RA, Gut RZ, Cooper DL. Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE). Haemophilia. 2012 May; 18(3):392-9.
      View in: PubMed
    6. Shander A, Walsh CE, Cromwell C. Acquired hemophilia: a rare but life-threatening potential cause of bleeding in the intensive care unit. Intensive Care Med. 2011 Aug; 37(8):1240-9.
      View in: PubMed
    7. Cimmino G, Giannarelli C, Chen W, Alique M, Santos-Gallego CG, Fuster V, Hajjar RJ, Walsh CE, Badimon JJ. Adeno-associated virus serotype 8 ApoA-I gene transfer reduces progression of atherosclerosis in ApoE-KO mice: comparison of intramuscular and intravenous administration. J Cardiovasc Pharmacol. 2011 Mar; 57(3):325-33.
      View in: PubMed
    8. Zhang G, Shi Q, Fahs SA, Kuether EL, Walsh CE, Montgomery RR. Factor IX ectopically expressed in platelets can be stored in alpha-granules and corrects the phenotype of hemophilia B mice. Blood. 2010 Aug 26; 116(8):1235-43.
      View in: PubMed
    9. Cimmino G, Chen W, Speidl WS, Giannarelli C, Ibanez B, Fuster V, Hajjar R, Walsh CE, Badimon JJ. Safe and sustained overexpression of functional apolipoprotein A-I/high-density lipoprotein in apolipoprotein A-I-null mice by muscular adeno-associated viral serotype 8 vector gene transfer. J Cardiovasc Pharmacol. 2009 Nov; 54(5):405-11.
      View in: PubMed
    10. Walsh CE, Valentino LA. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices. Haemophilia. 2009 Sep; 15(5):1014-21.
      View in: PubMed
    11. Ward P, Walsh CE. Chimeric AAV Cap sequences alter gene transduction. Virology. 2009 Apr 10; 386(2):237-48.
      View in: PubMed
    12. Walsh CE. Prophylaxis for adults with severe haemophilia: a compelling need for evidence-based guidelines. Haemophilia. 2008 Mar; 14(2):385-6.
      View in: PubMed
    13. Storek B, Harder NM, Banck MS, Wang C, McCarty DM, Janssen WG, Morrison JH, Walsh CE, Beutler AS. Intrathecal long-term gene expression by self-complementary adeno-associated virus type 1 suitable for chronic pain studies in rats. Mol Pain. 2006; 2:4.
      View in: PubMed
    14. Chao H, Walsh CE. RNA repair for haemophilia A. Expert Rev Mol Med. 2006; 8(1):1-8.
      View in: PubMed
    15. Walsh CE. Adeno-associated vectors: are we there yet? Gene Ther. 2005 Nov; 12(21):1539.
      View in: PubMed
    16. Yang Y, Walsh CE. Spliceosome-mediated RNA trans-splicing. Mol Ther. 2005 Dec; 12(6):1006-12.
      View in: PubMed
    17. Beutler AS, Banck MS, Walsh CE, Milligan ED. Intrathecal gene transfer by adeno-associated virus for pain. Curr Opin Mol Ther. 2005 Oct; 7(5):431-9.
      View in: PubMed
    18. Walsh CE. New paradigms for gene transfer: RNA trans-splicing and small interfering RNA as therapeutic strategies. Semin Hematol. 2004 Oct; 41(4):297-302.
      View in: PubMed
    19. Pipe SW, Saint-Remy JM, Walsh CE. New high-technology products for the treatment of haemophilia. Haemophilia. 2004 Oct; 10 Suppl 4:55-63.
      View in: PubMed
    20. Chao H, Walsh CE. AAV vectors for hemophilia B gene therapy. Mt Sinai J Med. 2004 Oct; 71(5):305-13.
      View in: PubMed
    21. Mansfield SG, Chao H, Walsh CE. RNA repair using spliceosome-mediated RNA trans-splicing. Trends Mol Med. 2004 Jun; 10(6):263-8.
      View in: PubMed
    22. Yamada K, Ramezani A, Hawley RG, Ebell W, Arwert F, Arnold LW, Walsh CE. Phenotype correction of Fanconi anemia group A hematopoietic stem cells using lentiviral vector. Mol Ther. 2003 Oct; 8(4):600-10.
      View in: PubMed
    23. Chao H, Mansfield SG, Bartel RC, Hiriyanna S, Mitchell LG, Garcia-Blanco MA, Walsh CE. Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. Nat Med. 2003 Aug; 9(8):1015-9.
      View in: PubMed
    24. Walsh CE. Gene therapy progress and prospects: gene therapy for the hemophilias. Gene Ther. 2003 Jun; 10(12):999-1003.
      View in: PubMed
    25. Yamada K, McCarty DM, Madden VJ, Walsh CE. Lentivirus vector purification using anion exchange HPLC leads to improved gene transfer. Biotechniques. 2003 May; 34(5):1074-8, 1080.
      View in: PubMed
    26. Walsh C. Gene therapy for hemophilia: are viral vectors really feasible? J Thromb Haemost. 2003 Feb; 1(2):218-9.
      View in: PubMed
    27. Rick ME, Walsh CE, Key NS. Congenital bleeding disorders. Hematology Am Soc Hematol Educ Program. 2003; 559-74.
      View in: PubMed
    28. Chao H, Walsh CE. Hemophilia gene therapy: novel rAAV vectors and RNA repair strategy. Curr Opin Mol Ther. 2002 Oct; 4(5):499-504.
      View in: PubMed
    29. Suwanmanee T, Sierakowska H, Lacerra G, Svasti S, Kirby S, Walsh CE, Fucharoen S, Kole R. Restoration of human beta-globin gene expression in murine and human IVS2-654 thalassemic erythroid cells by free uptake of antisense oligonucleotides. Mol Pharmacol. 2002 Sep; 62(3):545-53.
      View in: PubMed
    30. Chao H, Sun L, Bruce A, Xiao X, Walsh CE. Expression of human factor VIII by splicing between dimerized AAV vectors. Mol Ther. 2002 Jun; 5(6):716-22.
      View in: PubMed
    31. Walsh CE, Chao H. Parvovirus-mediated gene transfer for the haemophilias. Haemophilia. 2002 Mar; 8 Suppl 2:60-7.
      View in: PubMed
    32. Walsh CE. Gene therapy for the hemophilias. Curr Opin Pediatr. 2002 Feb; 14(1):12-6.
      View in: PubMed
    33. Chao H, Monahan PE, Liu Y, Samulski RJ, Walsh CE. Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. Mol Ther. 2001 Sep; 4(3):217-22.
      View in: PubMed
    34. Chao H, Walsh CE. Induction of tolerance to human factor VIII in mice. Blood. 2001 May 15; 97(10):3311-2.
      View in: PubMed
    35. Yamada K, Olsen JC, Patel M, Rao KW, Walsh CE. Functional correction of fanconi anemia group C hematopoietic cells by the use of a novel lentiviral vector. Mol Ther. 2001 Apr; 3(4):485-90.
      View in: PubMed
    36. Chao H, Liu Y, Rabinowitz J, Li C, Samulski RJ, Walsh CE. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther. 2000 Dec; 2(6):619-23.
      View in: PubMed
    37. Chao H, Mao L, Bruce AT, Walsh CE. Sustained expression of human factor VIII in mice using a parvovirus-based vector. Blood. 2000 Mar 1; 95(5):1594-9.
      View in: PubMed
    38. Gush KA, Fu KL, Grompe M, Walsh CE. Phenotypic correction of Fanconi anemia group C knockout mice. Blood. 2000 Jan 15; 95(2):700-4.
      View in: PubMed
    39. McMahon LW, Walsh CE, Lambert MW. Human alpha spectrin II and the Fanconi anemia proteins FANCA and FANCC interact to form a nuclear complex. J Biol Chem. 1999 Nov 12; 274(46):32904-8.
      View in: PubMed
    40. Chao H, Walsh CE. Endogenous canine FIX antigen exists in Chapel Hill strain hemophilia B canine. Thromb Haemost. 1999 Oct; 82(4):1378.
      View in: PubMed
    41. Liu JM, Kim S, Read EJ, Futaki M, Dokal I, Carter CS, Leitman SF, Pensiero M, Young NS, Walsh CE. Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene (FANCC). Hum Gene Ther. 1999 Sep 20; 10(14):2337-46.
      View in: PubMed
    42. Brois DW, McMahon LW, Ramos NI, Anglin LM, Walsh CE, Lambert MW. A deficiency in a 230 kDa DNA repair protein in fanconi anemia complementation group A cells is corrected by the FANCA cDNA. Carcinogenesis. 1999 Sep; 20(9):1845-53.
      View in: PubMed
    43. Walsh CE. Fetal gene therapy. Gene Ther. 1999 Jul; 6(7):1200-1.
      View in: PubMed
    44. Walsh CE, Yountz MR, Simpson DA. Intracellular localization of the Fanconi anemia complementation group A protein. Biochem Biophys Res Commun. 1999 Jun 16; 259(3):594-9.
      View in: PubMed
    45. Guillouf C, Wang TS, Liu J, Walsh CE, Poirier GG, Moustacchi E, Rosselli F. Fanconi anemia C protein acts at a switch between apoptosis and necrosis in mitomycin C-induced cell death. Exp Cell Res. 1999 Feb 1; 246(2):384-94.
      View in: PubMed
    46. Fu KL, Thuss PC, Fujino T, Digweed M, Liu JM, Walsh CE. Retroviral gene transfer for the assignment of Fanconi anemia (FA) patients to a FA complementation group. Hum Genet. 1998 Feb; 102(2):166-9.
      View in: PubMed
    47. Monahan PE, Samulski RJ, Tazelaar J, Xiao X, Nichols TC, Bellinger DA, Read MS, Walsh CE. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther. 1998 Jan; 5(1):40-9.
      View in: PubMed
    48. Fu KL, Foe JR, Joenje H, Rao KW, Liu JM, Walsh CE. Functional correction of Fanconi anemia group A hematopoietic cells by retroviral gene transfer. Blood. 1997 Nov 1; 90(9):3296-303.
      View in: PubMed
    49. Liu JM, Young NS, Walsh CE, Cottler-Fox M, Carter C, Dunbar C, Barrett AJ, Emmons R. Retroviral mediated gene transfer of the Fanconi anemia complementation group C gene to hematopoietic progenitors of group C patients. Hum Gene Ther. 1997 Sep 20; 8(14):1715-30.
      View in: PubMed
    50. Qazilbash MH, Xiao X, Seth P, Cowan KH, Walsh CE. Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53. Gene Ther. 1997 Jul; 4(7):675-82.
      View in: PubMed
    51. Liu JM, Poiley J, Devetten M, Kajigaya S, Walsh CE. The Fanconi anemia complementation group C gene (FAC) suppresses transformation of mutant fibroblasts by the SV40 virus. Biochem Biophys Res Commun. 1996 Jun 25; 223(3):685-90.
      View in: PubMed
    52. Walsh CE, Mann MM, Emmons RV, Wang S, Liu JM. Transduction of CD34-enriched human peripheral and umbilical cord blood progenitors using a retroviral vector with the Fanconi anemia group C gene. J Investig Med. 1995 Aug; 43(4):379-85.
      View in: PubMed
    53. Qazilbash MH, Walsh CE, Russell SM, Noguchi M, Mann MM, Leonard WJ, Liu JM. Retroviral vector for gene therapy of X-linked severe combined immunodeficiency syndrome. J Hematother. 1995 Apr; 4(2):91-8.
      View in: PubMed
    54. Liu JM, Kim S, Walsh CE. Retroviral-mediated transduction of the fanconi anemia C complementing (FACC) gene in two murine transplantation models. Blood Cells Mol Dis. 1995; 21(1):56-63.
      View in: PubMed
    55. Liu JM, Buchwald M, Walsh CE, Young NS. Fanconi anemia and novel strategies for therapy. Blood. 1994 Dec 15; 84(12):3995-4007.
      View in: PubMed
    56. Walsh CE, Nienhuis AW, Samulski RJ, Brown MG, Miller JL, Young NS, Liu JM. Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector. J Clin Invest. 1994 Oct; 94(4):1440-8.
      View in: PubMed
    57. Walsh CE, Grompe M, Vanin E, Buchwald M, Young NS, Nienhuis AW, Liu JM. A functionally active retrovirus vector for gene therapy in Fanconi anemia group C. Blood. 1994 Jul 15; 84(2):453-9.
      View in: PubMed
    58. Walsh CE, Liu JM, Miller JL, Nienhuis AW, Samulski RJ. Gene therapy for human hemoglobinopathies. Proc Soc Exp Biol Med. 1993 Dec; 204(3):289-300.
      View in: PubMed
    59. Miller JL, Walsh CE, Ney PA, Samulski RJ, Nienhuis AW. Single-copy transduction and expression of human gamma-globin in K562 erythroleukemia cells using recombinant adeno-associated virus vectors: the effect of mutations in NF-E2 and GATA-1 binding motifs within the hypersensitivity site 2 enhancer. Blood. 1993 Sep 15; 82(6):1900-6.
      View in: PubMed
    60. Walsh CE, Liu JM, Xiao X, Young NS, Nienhuis AW, Samulski RJ. Regulated high level expression of a human gamma-globin gene introduced into erythroid cells by an adeno-associated virus vector. Proc Natl Acad Sci U S A. 1992 Aug 1; 89(15):7257-61.
      View in: PubMed
    61. Walsh CE, Liu JM, Anderson SM, Rossio JL, Nienhuis AW, Young NS. A trial of recombinant human interleukin-1 in patients with severe refractory aplastic anaemia. Br J Haematol. 1992 Jan; 80(1):106-10.
      View in: PubMed
    Walsh's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067